Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

BACKGROUND: No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Kaley, Thomas J., Wen, Patrick, Schiff, David, Ligon, Keith, Haidar, Sam, Karimi, Sasan, Lassman, Andrew B., Nolan, Craig P., DeAngelis, Lisa M., Gavrilovic, Igor, Norden, Andrew, Drappatz, Jan, Lee, Eudocia Quant, Purow, Benjamin, Plotkin, Scott R., Batchelor, Tracy, Abrey, Lauren E., Omuro, Antonio
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483051/
https://ncbi.nlm.nih.gov/pubmed/25100872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou148
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky